12-29-8 ⓔ文献
Bosman FT, Carneiro F, et al: WHO World Health Organization classification of tumors and genetics of the digestive system. Lyon: IARC Press; 2010.
Ito T, Igarashi H, et al: Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol, 2012; 47: 941–960.
Ohki R, Saito K, et al: PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A, 2014; 10: E2404–2413.
Ito T, Sasano H, et al: Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol, 2010; 45: 234–243.
Ito T, Igarashi H, et al: Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol, 2015; 50: 58–64.
Lloyd RV, Osamura RY, et al eds: WHO Classification of Tumours of Endocrine Organs 4th ed, IARC Press, 2017.
日本神経内分泌腫瘍研究会編：膵・消化管神経内分泌腫瘍 (NEN) 診療ガイドライン 2019 第2版，金原出版，2019．
Yao JC, Shah MH, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011; 364: 514–523.
Raymond E, Dahan L, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 2011; 364: 1082.
Ito T, Okusaka T, et al: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well–differentiated pancreatic neuroendocrine tumor. Invest New Drugs, 2013; 31: 1265–1274.
Rinke A, Müller HH, et al: Placebo–controlled, double–blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol, 2009; 27: 4656–4663.
Caplin ME, Pavel M, et al: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med, 2014; 371: 224–233.
Ito T, Honma Y, et al: Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well–differentiated neuroendocrine tumors. Invest New Drugs, 2017; 35: 499–508.